We are live on ! Find out more
TRAX icon

First Tracks Biotherapeutics

182 hedge funds and large institutions have $1.28B invested in First Tracks Biotherapeutics in 2026 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 70 increasing their positions, 43 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

310% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $418K

188% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 17

63% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 43

59% more capital inflows, than outflows

Capital inflows: $302M | Capital outflows: $190M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

21% more funds holding

Funds holding: 150 → 182 (+32)

3.69% more ownership

Funds ownership: 97.7% → 101.38% (+3.7%)

Holders
182
Holders Change
+32
Holders Change %
+21.33%
% of All Funds
2.21%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
49
Increased
70
Reduced
43
Closed
17
Calls
$1.71​M
Puts
$418​K
Net Calls
+$1.29​M
Net Calls Change
+$1.3​M

TRAX Hedge Fund Activity: Q3 2026 in Review

182 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in First Tracks Biotherapeutics (TRAX) for Q3 2026, worth a combined $1.28B — up 87% from $686M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new TRAX positions and 17 closed out — a net gain of 32 holders — while 70 added to existing stakes and 43 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $52.6M. The largest seller was Vestal Point Capital, cutting an estimated $32.9M.

  • 182 institutional investors held First Tracks Biotherapeutics (TRAX) as of Q3 2026, up from 150 in Q2 2026.
  • Funds reported $1.28B of First Tracks Biotherapeutics stock for Q3 2026, up 87% quarter-over-quarter.
  • 49 funds opened new First Tracks Biotherapeutics positions in Q3 2026 and 17 closed out, a net change of +32 holders.
  • The largest First Tracks Biotherapeutics buyer in Q3 2026 was Adage Capital Partners, an estimated $52.6M added.
  • The largest First Tracks Biotherapeutics seller in Q3 2026 was Vestal Point Capital, an estimated $32.9M sold.

Based on aggregated 13F filings for Q3 2026.